HC Wainwright Issues Negative Estimate for DRUG Earnings
Research analysts at HC Wainwright decreased their Q3 2025 earnings estimates for shares of Bright Minds Biosciences in a ...
Equities Analysts Issue Forecasts for AVXL Q2 Earnings
Stock analysts at HC Wainwright lifted their Q2 2025 earnings per share (EPS) estimates for shares of Anavex Life Sciences in ...
H.C. Wainwright says SEC plan to dismiss suit lifts ‘major overhang’ on Coinbase
H.C. Wainwright analyst Mike Colonnese notes that Coinbase (COIN) announced that the Securities and Exchange Commission has agreed to dismiss ...
H.C. Wainwright Sticks to Its Hold Rating for Biotricity (BTCY)
H.C. Wainwright analyst Kevin Dede maintained a Hold rating on Biotricity (BTCY – Research Report) today. The company’s shares closed yesterday ...
Hosted on MSN14d
HC Wainwright & Co. Initiates Coverage of Vertical Aerospace (EVTL) with Buy Recommendation
Fintel reports that on February 7, 2025, HC Wainwright & Co. initiated coverage of Vertical Aerospace (NYSE:EVTL) with a Buy recommendation. Analyst Price Forecast Suggests 94.58% Upside As of ...
Investing18d
H.C. Wainwright maintains buy rating on Tenaya Therapeutics stock
On Tuesday, H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Tenaya Therapeutics Inc (NASDAQ:TNYA), with a price target of $18.00. This aligns with the strong overall analyst ...
Investing18d
H.C. Wainwright maintains buy on Northern Dynasty stock
Tuesday, H.C. Wainwright reaffirmed its Buy rating on Northern Dynasty Minerals (NYSE:NAK) with a steady price target of $1.30, representing significant upside from the current trading price of $0.65.
Nasdaq19d
HC Wainwright & Co. Initiates Coverage of CRISPR Therapeutics (BRSE:1CG) with Buy Recommendation
Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (BRSE:1CG) with a Buy recommendation. There are 575 funds or institutions reporting positions ...